东莞控股：东阳光药在HECN30227Ⅰ期临床及小核酸平台研发等取得一定进展

Core Viewpoint - Dongguan Holdings announced progress in the development of HECN30227, a siRNA drug targeting hepatitis B virus, and advancements in the small nucleic acid platform research [1] Group 1 - Dongguan Holdings responded to investor inquiries on its interactive platform [1] - Dongyangguang Pharmaceutical has made certain advancements in the clinical phase I of HECN30227 [1] - Further details can be found in the relevant announcements released by Dongyangguang Pharmaceutical [1]